Effects of HZ08, a novel P-glycoprotein inhibitor, on the reversal of P-glycoprotein mediated multidrug resistance in nude mice and cytochrome P-450 activities in rat liver microsomes

Journal of China Pharmaceutical University

Volumn 39, Issue 5, 2008, Pages 447-452

  Yan, Fang ^a   Li, Yun Man ^a   Wang, Qiu Juan ^a   Fang, Wei Rong ^a   Kang, Kai ^a   Zhang, Lu Yong ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Cytochrome P450 enzyme; HZ08; Nude mice; P glycoprotein inhibitor; Tumor multidrug resistance

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; DOXORUBICIN; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; HZ 08; ISOENZYME; UNCLASSIFIED DRUG; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CELL STRAIN K 562; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER MICROSOME; MALE; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; NUDE MOUSE; RAT; SOLID TUMOR;

EID: 55749106727     PISSN: 10005048     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Gottesman MM, Pastan I, Ambudkar SV. P-glycoprotein and multidrug resistance [J]. Curr Opin Gene Dev, 1996, 6(5): 610-617.
2. Keppler D, Cui Y, König J, et al. Export pumps for anionic conjugates encoded by MRP genes [J]. Adv Enzyme Regal, 1999,39: 237-246.
3. Tsuruo T, Iida H, Tsukagoshi S, et al. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil [J]. Cancer Res,1981,41(5):1 967-1 972.
4. Ford JM, Bruggemann EP, Pastan I, et al. Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines [J]. Cancer Res,1990, 50(6):1 748-1 756.
5. Bates SE, Wilson WH, Fojo AT, et al. Clinical reversal of multidrug resistance [J]. Stem Cells,1996,14(1):56-63.
6. Lum BL, Kaubisch S, Yahanda AM, et al. Alteration of etoposide pharmacokinetics and pbarmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance [J]. J Clin Oncol, 1992,10(10):1 635-1 642.
7. Tolcher AW, Cowan KH, Solomon D, et al. A. Phase I crossover study of paclitaxel with R-verapamil in patients with metastatic breast cancer [J]. J Clin Oncol,1996,14(4):1 173-1 184.
8. Hardman JG, Limbird LE, Molinoff PB, et al i. The Pharmalological Basis of Therapeutics[M]. New York: McGraw-Hill, 1996:14-18.
9. Szakács G, Paterson JK, Ludwig JA, et al. Targeting multidrug resistance in cancer [J]. Nat Rev Drug Discov,2006,5(3):219-234.
10. Schuetz EG, Beck WT, Schuetz JD. Modulators and substrates of Pglycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells [J]. Mol Pharmacol, 1996,49(2):311-318.
11. Schuetz EG, Schimkel AH, Relling MV, et al. P-glycoprotein: A major determinant of rifampicin-inducible expression of cytochrome P4503 A in mice and humans [J]. Proc Natl Acad Sci USA, 1996,93(9):4 001-4 005.
12. Yan F, Jiang Y, Li YM, et al. Reversal of P-glycoprotein and multidrug resistance-associated protein 1 mediated multidrug resistance in cancer cells by HZ08 isomers, Tetrataisohydroquinolin derivatives [J]. Biol Pharm Bull,2008,31(6):1 258-1 264.
13. Wormhoudt LW, Ploemen JH, Commandeur JN, et al. Cytochrome P450 catalyzed metabolism of 1 2-dibromoethane in liver microsomes of differentially induced rats [J]. Chem Biol Interact, 1996,99(1-3):41-53.
14. Weng JY, Song M, Hang TJ, et al. Pharmacokineties of HM08 in rats by liquid chromatography-tandem mass spectrometry [J]. J Chromatogr B,2007, 856(1-2):29-34.
15. Guengerich FP. Cytochromes P450, drugs, and diseases [J]. Mol Interv,2003, 3(4):194-204.